EA201270108A1 - Формирование полиспецифического t-клеточного ответа против вич у человека - Google Patents
Формирование полиспецифического t-клеточного ответа против вич у человекаInfo
- Publication number
- EA201270108A1 EA201270108A1 EA201270108A EA201270108A EA201270108A1 EA 201270108 A1 EA201270108 A1 EA 201270108A1 EA 201270108 A EA201270108 A EA 201270108A EA 201270108 A EA201270108 A EA 201270108A EA 201270108 A1 EA201270108 A1 EA 201270108A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polyspecific
- human
- formation
- response against
- cell response
- Prior art date
Links
- 230000005867 T cell response Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 1
- 241000700618 Vaccinia virus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24964409P | 2009-10-08 | 2009-10-08 | |
| EP10001264 | 2010-02-08 | ||
| PCT/EP2010/006114 WO2011042180A1 (en) | 2009-10-08 | 2010-10-06 | Generation of a broad t-cell response in humans against hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201270108A1 true EA201270108A1 (ru) | 2012-08-30 |
Family
ID=46396898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270108A EA201270108A1 (ru) | 2009-10-08 | 2010-10-06 | Формирование полиспецифического t-клеточного ответа против вич у человека |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120135032A1 (enExample) |
| EP (1) | EP2486138A1 (enExample) |
| JP (1) | JP2013507107A (enExample) |
| KR (1) | KR20120093941A (enExample) |
| CN (1) | CN102656271A (enExample) |
| AU (1) | AU2010305030A1 (enExample) |
| CA (1) | CA2767924A1 (enExample) |
| EA (1) | EA201270108A1 (enExample) |
| MX (1) | MX2012002531A (enExample) |
| SG (1) | SG178909A1 (enExample) |
| WO (1) | WO2011042180A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| AU2014231229A1 (en) * | 2013-03-15 | 2015-09-17 | Bavarian Nordic A/S | Single high dose of MVA induces a protective immune response in neonates and infants |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV |
| US20220249653A1 (en) * | 2019-06-27 | 2022-08-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for detecting hiv latency, treating hiv infection, and reversing hiv latency |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| CA2392877C (en) | 1999-12-23 | 2011-11-15 | Tomas Hanke | Improvements in or relating to immune responses to hiv |
| CN1312171C (zh) * | 2000-07-14 | 2007-04-25 | 宾夕法尼亚州立大学托管会 | 可编码hiv辅助蛋白的dna疫苗 |
| UA76731C2 (uk) * | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60205388T2 (de) | 2001-12-10 | 2006-03-30 | Bavarian Nordic A/S | Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| CN1982332A (zh) * | 2002-05-16 | 2007-06-20 | 巴法里安诺迪克有限公司 | Hiv调节/辅助蛋白的融合蛋白 |
| DK1506301T3 (da) | 2002-05-16 | 2014-07-21 | Bavarian Nordic As | Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet |
| US20060029619A1 (en) | 2002-05-16 | 2006-02-09 | Paul Howley | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter |
| JP5122983B2 (ja) | 2005-02-24 | 2013-01-16 | メディカル リサーチ カウンシル | Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用 |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| JP2010522761A (ja) | 2007-03-26 | 2010-07-08 | インターナショナル エイズ バクシーン イニシアティブ | 改変ｍｖａウイルスｈｉｖ−１ベクターを用いて免疫応答を誘発する方法 |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| WO2009056535A2 (en) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
-
2010
- 2010-10-06 US US13/389,411 patent/US20120135032A1/en not_active Abandoned
- 2010-10-06 WO PCT/EP2010/006114 patent/WO2011042180A1/en not_active Ceased
- 2010-10-06 SG SG2012013983A patent/SG178909A1/en unknown
- 2010-10-06 MX MX2012002531A patent/MX2012002531A/es not_active Application Discontinuation
- 2010-10-06 JP JP2012532489A patent/JP2013507107A/ja not_active Withdrawn
- 2010-10-06 EP EP10765582A patent/EP2486138A1/en not_active Withdrawn
- 2010-10-06 CN CN2010800415531A patent/CN102656271A/zh active Pending
- 2010-10-06 KR KR1020127011933A patent/KR20120093941A/ko not_active Withdrawn
- 2010-10-06 AU AU2010305030A patent/AU2010305030A1/en not_active Abandoned
- 2010-10-06 EA EA201270108A patent/EA201270108A1/ru unknown
- 2010-10-06 CA CA2767924A patent/CA2767924A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011042180A1 (en) | 2011-04-14 |
| SG178909A1 (en) | 2012-04-27 |
| KR20120093941A (ko) | 2012-08-23 |
| MX2012002531A (es) | 2012-04-11 |
| US20120135032A1 (en) | 2012-05-31 |
| CA2767924A1 (en) | 2011-04-14 |
| CN102656271A (zh) | 2012-09-05 |
| JP2013507107A (ja) | 2013-03-04 |
| AU2010305030A1 (en) | 2012-05-10 |
| EP2486138A1 (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201270108A1 (ru) | Формирование полиспецифического t-клеточного ответа против вич у человека | |
| JP2012509340A5 (enExample) | ||
| JP2013507107A5 (enExample) | ||
| CY1113288T1 (el) | Ανασυνδυασμενοι φορεις που βασιζονται επι του τροποποιημενου ιου αγκυρας (mva) ως αποτρεπτικα και θεραπευτικα εμβολια εναντι aids | |
| HK1207829A1 (zh) | 疫苗 | |
| ATE546540T1 (de) | Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen | |
| WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
| NZ597458A (en) | Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means | |
| WO2007144720A3 (en) | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients | |
| EA201290956A1 (ru) | Вакцина против вич | |
| EA201000829A1 (ru) | Вакцина | |
| Kloverpris et al. | Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes | |
| WO2010041241A3 (en) | Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding | |
| Caputo et al. | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development | |
| WO2006026667A3 (en) | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes | |
| Vermeire et al. | The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection | |
| PH12012501930A1 (en) | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer | |
| ATE486088T1 (de) | Hiv-impfstoff | |
| MX354571B (es) | Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). | |
| ES2399875T3 (es) | Composiciones de vacunas de ADN y procedimientos para su uso | |
| Ueno et al. | Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide | |
| Yu et al. | Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? | |
| Pal et al. | Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1 | |
| Borsetti et al. | Viral outcome of simian–human immunodeficiency virus SHIV-89.6 P adapted to cynomolgus monkeys | |
| WO2007143606A3 (en) | Hiv-1 clade a consensus sequences, antigens, and transgenes |